SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets nod to conduct Phase III trial of Desidustat in sickle cell disease

23 Jul 2026 Evaluate

Zydus Lifesciences has received permission to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease. Conducted in collaboration with the Indian Council of Medical Research (ICMR), the 203-day study will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia. The trial will enrol 164 patients diagnosed with the disease.

The company and ICMR had successfully completed the Phase II Proof-of-concept (PoC) trial to evaluate the efficacy and safety of Desidustat oral tablet for treatment of sickle cell disease. The study met its primary endpoint, demonstrating positive outcomes in line with the trial objectives. The Phase III trial will be a double blind, randomised, placebo controlled, parallel, multicentre, study to evaluate the efficacy and safety of Desidustat oral tablets for treatment of anaemia in sickle cell disease patients.

Zydus Lifesciences (formerly known as Cadila Healthcare) operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

1110.00 2.00 (0.18%)
28-Jul-2026 10:44 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1986.60
Dr. Reddys Labs. 1145.65
Cipla 1432.90
Lupin 2406.00
Zydus Lifesciences 1110.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: